MedTech Atlas
Back to medical device regulatory guideAll countries
Middle East & AfricaENPublic regulatory overview

Nigeria

Market Overview Population: Approximately 220 million (2024), the most populous country in Africa and the largest economy in Africa by GDP Healthcare System: Predominantly public h...

Updated: 2026-05-04

You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.

Sign in / register for full country report
Reference approval strategy

FDA / CE / MDSAP / NMPA benefits for this market

These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.

US FDA

510(k) / De Novo / PMAModerate benefit

FDA evidence is useful technical and clinical support, but the local authority still performs an independent review.

Likely benefit
  • Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
  • May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
  • Does not remove local holder, language, labeling, fee, import, or post-market obligations.
View topic

EU CE

MDR / IVDRStrong benefit

CE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.

Likely benefit
  • Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
  • Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
  • Does not replace local registration or local representative responsibilities outside the CE-recognized route.
View topic

MDSAP

Single QMS auditIndirect QMS signal

MDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.

Likely benefit
  • Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
  • Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
  • Does not authorize product sale and does not replace safety, performance, or clinical evidence.
View topic

China NMPA

China registration / filingSupportive evidence

NMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.

Likely benefit
  • Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
  • Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
  • Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
View topic

AI Citation Summary

  • Country: Nigeria
  • Product line: Medical devices
  • Regulator / source: Regulatory Maturity: Medium-low; NAFDAC (National Agency for Food and Drug Administration and Control) has a high public profile but limited regulatory capacity; the registration process has relatively low transparency and actual timelines are highly unpredictable
  • Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
  • Typical timeline: Regulatory Maturity: Medium-low; NAFDAC (National Agency for Food and Drug Administration and Control) has a high public profile but limited regulatory capacity; the registration process has relatively low transparency and actual timelines are highly unpredictable
  • Key fees: Regulatory route - Which product category, risk class, application type, reliance route, or special pathway applies? - Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
  • Local requirement: Nigeria medical-device entry should be separated into NAFDAC / Standards Organisation of Nigeria interfaces regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
  • Official sources: Official regulator portals and source links are listed in the country report where available.
  • Last verified: 2026-05-04
  • Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
  • Preferred citation: MedTech Atlas

Market Overview

  • Population: Approximately 220 million (2024), the most populous country in Africa and the largest economy in Africa by GDP
  • Healthcare System: Predominantly public hospitals (Federal Teaching Hospitals, State Hospitals), but infrastructure is generally weak; private healthcare is growing rapidly (especially in Lagos, Abuja, and other major cities); the National Health Insurance Authority (NHIA, consolidating the former NHIS) is advancing Universal Health Coverage; healthcare resources are severely imbalanced between the north and south
  • Market Characteristics: A large but fragmented market with non-transparent procurement systems; highly import-dependent (virtually no domestic medical device manufacturing); counterfeit products are a serious problem; numerous private clinics/hospitals; access to foreign exchange (US dollar supply) is a long-standing challenge
  • Regulatory Maturity: Medium-low; NAFDAC (National Agency for Food and Drug Administration and Control) has a high public profile but limited regulatory capacity; the registration process has relatively low transparency and actual timelines are highly unpredictable

Market-Entry Logic

Nigeria medical-device entry should be separated into NAFDAC / Standards Organisation of Nigeria interfaces regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.

Entry layer Key question Practical view
Regulatory route Which product category, risk class, application type, reliance route, or special pathway applies? Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
Local execution Who holds the registration, imports, answers regulator questions, manages safety reporting, and controls renewals or variations? Contract structure matters because local agents, sponsors, distributors, or licence holders can control practical market access even when the foreign manufacturer owns the product
Evidence and economics What clinical, quality, performance, HTA, pricing, and budget-impact evidence is needed? Registration evidence and payer evidence should be planned together; otherwise approval may be achieved without reimbursement, tender access, or hospital adoption
Channel access Which payer, hospital, distributor, retail, tender, or private-care channel will create volume? Start with the channel that matches product value and service burden; premium products often need reference sites before broad tender or retail expansion

Main Players and Channel Map

Type Representative players Market meaning
Regulator / review NAFDAC / Standards Organisation of Nigeria interfaces Determines approval route, technical evidence, inspections, labelling, post-market duties, renewals, and variations
Payment / procurement NHIA, state procurement, donor programmes, private hospitals and retail pharmacy chains Determines reimbursement, tender economics, price ceilings, purchasing lists, and patient affordability
Companies / channels local importers, Lagos / Abuja private hospitals, teaching hospitals, diagnostic chains, donor procurement channels and multinational medtech companies Shows the competitive set, partner universe, distribution power, hospital access points, and local execution benchmarks
End users / buyers Public hospitals, private hospital groups, specialist centers, laboratories, pharmacies, insurers, and regional distributors Determine adoption, tender volume, reference cases, service expectations, and receivables risk
  1. Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
  2. Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
  3. Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
  4. Pricing pressure is structural: NAFDAC digitisation, import dependence, FX scarcity, counterfeit control, local manufacturing policy, distributor fragmentation and private diagnostic growth are reshaping launch sequencing and product economics.
  5. Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.

Regulatory Authority

  • Competent Authority: National Agency for Food and Drug Administration and Control (NAFDAC), subordinate to the Federal Ministry of Health (FMOH); the Medical Devices and Packaged Water Directorate handles specific registration matters
  • Official Portal: https://www.nafdac.gov.ng; online submission system: NAFDAC Integrated Regulatory Information System (NARIS)
  • Key Regulations:
    • NAFDAC Act (CAP N1 LFN 2004) and amendments
    • Medical Devices (Importation) Regulations
    • Food and Drug Administration Act
    • NAFDAC Medical Devices Guidelines (multiple versions; review the latest version)
    • Federal Ministry of Health Medical Devices Policy

Device Classification System

Local Class Risk Level EU Equivalent FDA Equivalent Description
Class A Low risk EU Class I / FDA Class I Simplified registration, basic documentation
Class B Medium risk EU Class IIa–IIb / FDA Class II Standard registration; Technical File required
Class C High risk EU Class III / FDA Class III Full registration review; clinical evidence required

NAFDAC classification follows GHTF classification principles; some device classifications may be inconsistent with international practice — confirm classification with a local consultant before registration. IVDs follow the GHTF IVD classification framework.

Registration Pathways

During the limited-time free period, sign in or register to view the complete medical device country report.